SEARCH

SEARCH BY CITATION

References

  • 1
    El Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817-823.
  • 2
    Davila JA, Morgan RO, Shaib Y, McGlynn KA, El Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 1372-1380.
  • 3
    El Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160: 3227-3230.
  • 4
    Hassan MM, Frome A, Patt YZ, El Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 2002; 35: 266-269.
  • 5
    Kulkarni K, Barcak E, El Serag H, Goodgame R. The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States. Aliment Pharmacol Ther 2004; 20: 445-450.
  • 6
    Liu JH, Chen PW, Asch SM, Busuttil RW, Ko CY. Surgery for hepatocellular carcinoma: does it improve survival? Ann Surg Oncol 2004; 11: 298-303.
  • 7
    El Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006; 44: 158-166.
  • 8
    Kim WR, Gores GJ, Benson JT, Therneau TM, Melton LJ III. Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology 2005; 129: 486-493.
  • 9
    Chalasani N, Horlander JC Sr, Said A, Hoen H, Kopecky KK, Stockberger SMJr, et al. Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol 1999; 94: 2988-2993.
    Direct Link:
  • 10
    Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
  • 11
    Bruix J, Sherman M. Management of hepatocellular carcinoma. HEPATOLOGY 2005; 42: 1208-1236.
  • 12
    Colombo M. Screening for hepatocellular carcinoma. Digestion 1998; 59( Suppl. 2): 70-71.
  • 13
    McMahon BJ, London T. Workshop on screening for hepatocellular carcinoma. J Natl Cancer Inst 1991; 83: 916-919.
  • 14
    Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma. J Clin Gastroenterol 2002; 35( Suppl. 2): S86-S91.
  • 15
    Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52( Suppl. 3): iii1-iii8.
  • 16
    Sherman M. Screening for hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol 1999; 13: 623-635.
  • 17
    Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 2001; 16: 553-559.
  • 18
    Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnu L, Zoli M, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002; 97: 734-744.
    Direct Link:
  • 19
    Trevisani F, Cantarini MC, Labate AM, De Notariis S, Rapaccini G, Farinati F, et al. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol 2004; 99: 1470-1476.
    Direct Link:
  • 20
    Wong LL, Limm WM, Severino R, Wong LM. Improved survival with screening for hepatocellular carcinoma. Liver Transpl 2000; 6: 320-325.
  • 21
    Yang B, Zhang B, Xu Y, Wang W, Shen Y, Zhang A, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997; 123: 357-360.
  • 22
    Yu EW, Chie WC, Chen TH. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients? Cancer J 2004; 10: 317-325.
  • 23
    Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. HEPATOLOGY 2000; 31: 330-335.
  • 24
    Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422.
  • 25
    Davila JA, Weston A, Smalley W, El Serag HB. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol 2007; 41: 777-782.
  • 26
    Leykum LK, El Serag HB, Cornell J, Papadopoulos KP. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol 2007; 5: 508-512.
  • 27
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002; 40( Suppl.): IV-18.
  • 28
    World Health Organization. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
  • 29
    Kramer JR, Davila JA, Miller ED, Richardson P, Giordano TP, El Serag HB. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther 2008; 27: 274-282.
  • 30
    Harman HH. Modern Factor Analysis. 3rd ed. Chicago: The University of Chicago Press; 1976.
  • 31
    Kaiser HF. The varimax criterion for analytic rotation in factor analysis. Psychometrika 1958; 23: 187-200.
  • 32
    Yucel R, Zaslavsky AM. Imputation of binary treatment variables with measurement error in administrative data. J Am Stat Assoc 2005; 100: 1123-1132.
  • 33
    Zheng H, Yucel R, Ayanian JZ, Zaslavsky AM. Profiling providers on use of adjuvant chemotherapy by combining cancer registry and medical record data. Med Care 2006; 44: 1-7.
  • 34
    Meng X, Rubin DB. Performing likelihood ratio tests with multiply-imputed data sets. Biometrika 1992; 79: 103-111.
  • 35
    Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care 2002; 40( Suppl.): IV-35.
  • 36
    Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons; 1989.
  • 37
    Farinati F, Sergio A, Giacomin A, Di Nolfo MA, Del Poggio P, Benvegnù L, et al. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? Eur J Gastroenterol Hepatol 2009; 21: 1212-1218.
  • 38
    Trevisani F, Santi V, Gramenzi A, Di Nolfo MA, Del Poggio P, Benvegnu L, et al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? Am J Gastroenterol 2007; 102: 2448-2457.
    Direct Link: